Analyst Gil Blum of Needham reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report), retaining the price target of $10.00.
Gil Blum has given his Buy rating due to a combination of factors that highlight Autolus Therapeutics’ promising financial and operational performance. The company reported a robust first quarter with $9 million in initial sales of Aucatzyl, indicating strong market demand. This positive sales momentum has led to an upward revision of the full-year sales forecast from $27 million to $49 million, reflecting confidence in continued growth.
Moreover, Autolus has expanded its activated treatment centers from 33 to 39, with plans to reach 60, demonstrating strategic expansion efforts. The company’s financial health is further underscored by its substantial cash reserves of $517 million, which provide a solid foundation for future operations. Additionally, as manufacturing scales up, improved gross margins are anticipated, enhancing profitability prospects. These factors collectively support the Buy rating and a target price of $10.
According to TipRanks, Blum is an analyst with an average return of -11.5% and a 32.34% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Immunocore Holdings, and Autolus Therapeutics.